Skip Navigation

European Heart Journal 1996 17(12):1836-1840;
Copyright © 1996 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Zeymer, U.
Right arrow Articles by Neuhaus, K.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zeymer, U.
Right arrow Articles by Neuhaus, K.-L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1996 The European Society of Cardiology

Recombinant hirudin (HBW 023) produces stable anticoagulation unaffected by circadian variation in patients with thrombolysis for acute myocardial infarction

U. Zeymer, M. Mateblowski and K.-L. Neuhaus

Medizinische Klinik II, Städtische Kliniken Kassel Germany

Received 19 February 1996; accepted 26 February 1996.

Correspondence: Dr Uwe Zeymer, Städtische Kliniken Kassel, Medizinische Klinik II Mönchebergstrasse 41-43. D-34125 Kassel, Germany

Abstract

BACKGROUND: Circadian variations have been described for a number of haemostatic and physiological factors, all of which might predispose towards clotting in the late morning. The anticoagulation effect of heparin has been shown to respond in a circadian manner, resulting in minimal prolongation of the activated partial thromboplastin time (aPTT) in the morning.

METHODS: Recombinant hirudin (HBW 023) given as a bolus of 0.07, 0.1, 0.2 or 0.4 mg.kg–1 followed by an infusion of 0.05, 0.06, 0.1 or 0.15 mg. kg–1 over 48 h was used as conjunctive therapy to thrombolysis with frontloaded recombinant tissue-type plasminogen activator (100 mg . 90 min–1) in 40 patients with acute myocardial infarction. APTT, activated clotting time and free hirudin plasma levels were determined at baseline and at 8, 12, 16, 20, 24, 32, 40 and 48 h.

RESULTS: The prolongation of aPTT and activated clotting time was dose-dependent and stable. In 82.5% of the patients, aPTT values were ranged between the highest and the lowest aPTT of <30 s. When the results were divided into four time intervals (0000–0600, 0600–1200, 1200–1800, 1800–2400) neither in the individual patients nor in the mean values of the four different dose groups was any significant circadian variation in aPTT or activated clotting time prolongation observed. The pharmacokinetic studies of free hirudin plasma levels revealed no circadian rhythm either. All but one patient (97.5%) had a patent vessel (TIMI grade 2/3) at the end of the hirudin infusion.

CONCLUSIONS: Recombinant hirudin, in contrast to heparin, does not show any circadian variation in its anticoagulation effect. This might, in part, explain the more stable and predictable anticoagulation achieved by hirudin, which is associated with a reduced rate of reocclusions after thrombolysis.

Key Words: Thrombolysis • acute myocardial infarction • anticoagulation • recombinant hirudin


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.